Roth Capital Issues Pessimistic Outlook for Stryker Earnings

Stryker Co. (NYSE:SYK) – Analysts at Roth Capital decreased their Q2 2025 earnings per share (EPS) estimates for Stryker in a research report issued on Thursday, May 1st. Roth Capital analyst J. Wittes now anticipates that the medical technology company will post earnings of $3.04 per share for the quarter, down from their previous estimate of $3.13. The consensus estimate for Stryker’s current full-year earnings is $13.47 per share. Roth Capital also issued estimates for Stryker’s Q3 2025 earnings at $3.25 EPS, Q4 2025 earnings at $4.32 EPS, FY2025 earnings at $13.45 EPS, Q2 2026 earnings at $3.52 EPS, Q3 2026 earnings at $3.65 EPS and Q4 2026 earnings at $4.66 EPS.

Several other equities analysts also recently commented on SYK. Roth Mkm upped their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. BTIG Research set a $403.00 price target on Stryker and gave the company a “buy” rating in a research report on Monday, April 14th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $425.84.

Stryker Trading Down 0.9 %

NYSE:SYK opened at $377.77 on Monday. The firm has a market capitalization of $144.19 billion, a P/E ratio of 48.68, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $365.95 and a 200 day moving average of $374.03. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.68 billion. During the same period in the previous year, the firm earned $2.50 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its holdings in Stryker by 6.2% in the third quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company’s stock worth $143,934,000 after buying an additional 23,329 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Stryker by 15.8% during the fourth quarter. Nordea Investment Management AB now owns 971,735 shares of the medical technology company’s stock valued at $350,485,000 after acquiring an additional 132,513 shares in the last quarter. CWA Asset Management Group LLC raised its holdings in Stryker by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 3,854 shares of the medical technology company’s stock worth $1,388,000 after acquiring an additional 131 shares during the last quarter. Regent Peak Wealth Advisors LLC bought a new position in Stryker in the 4th quarter valued at approximately $204,000. Finally, Bath Savings Trust Co boosted its stake in Stryker by 0.7% during the 4th quarter. Bath Savings Trust Co now owns 113,412 shares of the medical technology company’s stock valued at $40,834,000 after purchasing an additional 823 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.